It's time to revisit these top picks as we are more than halfway through a tumultuous 2022. AbbVie and VICI have vastly outperformed the market, but Alphabet is struggling.
### Instruction: What is the sentiment of this news? Please choose an answer from {negative/neutral/positive}
### Input: It's time to revisit these top picks as we are more than halfway through a tumultuous 2022. AbbVie and VICI have vastly outperformed the market, but Alphabet is struggling.
### Response: mildly negative